Deoxycytidine Kinase (DCK) (Middle Region) Peptide
DCK
Reactivité: Humain
Hôte: Synthetic
BP, WB
N° du produit ABIN975623
150,78 €
Plus frais de livraison 40,00 € et TVA
100 μg
Destination:
France
Envoi sous 15 à 22 jours ouvrables
Aperçu rapide pour Deoxycytidine Kinase (DCK) (Middle Region) Peptide (ABIN975623)
Antigène
DCK
(Deoxycytidine Kinase (DCK))
Origine
Humain
Source
Synthetic
Application
Blocking Peptide (BP), Western Blotting (WB)
-
-
Protein Region
- Middle Region
-
Attributs du produit
- This is a synthetic peptide designed for use in combination with anti-DCK antibody (Catalog #: ARP51775_P050). It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
-
Purification
- Purified
-
-
-
-
Indications d'application
- Each Investigator should determine their own optimal working dilution for specific applications.
-
Restrictions
- For Research Use only
-
-
-
Format
- Lyophilized
-
Reconstitution
- Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
-
Concentration
- 1 mg/mL
-
Buffer
- Final peptide concentration is 1 mg/mL in PBS.
-
Conseil sur la manipulation
- Avoid repeated freeze-thaw cycles.
-
Stock
- -20 °C
-
Stockage commentaire
- For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
-
-
- DCK (Deoxycytidine Kinase (DCK))
-
Sujet
-
Deoxycytidine kinase (DCK) is required for the phosphorylation of several deoxyribonucleosides and their nucleoside analogs. Deficiency of DCK is associated with resistance to antiviral and anticancer chemotherapeutic agents. Conversely, increased deoxycytidine kinase activity is associated with increased activation of these compounds to cytotoxic nucleoside triphosphate derivatives. DCK is clinically important because of its relationship to drug resistance and sensitivity.Deoxycytidine kinase (DCK) is required for the phosphorylation of several deoxyribonucleosides and their nucleoside analogs. Deficiency of DCK is associated with resistance to antiviral and anticancer chemotherapeutic agents. Conversely, increased deoxycytidine kinase activity is associated with increased activation of these compounds to cytotoxic nucleoside triphosphate derivatives. DCK is clinically important because of its relationship to drug resistance and sensitivity. Publication Note: This RefSeq record includes a subset of the publications that are available for this gene. Please see the Entrez Gene record to access additional publications.
Alias Symbols: MGC117410, MGC138632
Protein Interaction Partner: DDX19B,GOLM1,MED19,DDX19B,GOLM1,MED19
Protein Size: 260 -
Poids moléculaire
- 30 kDa
-
ID gène
- 1633
-
NCBI Accession
- NM_000788, NP_000779
-
UniProt
- P27707
Antigène
-
Vous êtes ici:
